Health Trials

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

ConditionHepatocellular Carcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSuzhou Zelgen Biopharmaceuticals Co.,Ltd

About this trial

This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.

Eligibility criteria

Qualifiers

Fully understand the study and voluntarily sign the informed consent form.

18-75 years of age;

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1；

Life expectancy ≥ 12 weeks.

Disqualifiers

Patients were deemed unsuitable for participating in the study by the investigator for any reasons.

Trial design

Treatments tested in this trial

  • ZG005 for Injection
  • Bevacizumab
  • Sintilimab
  • Bevacizumab

Treatment groups

90 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Lead sponsor

Source ClinicalTrials.gov